Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Current Pharmaceutical Biotechnology
Title: Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Volume: 7 Issue: 6
Author(s): Maurizio Zangari, Federica Cavallo and Guido Tricot
Affiliation:
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Export Options
About this article
Cite this article as:
Zangari Maurizio, Cavallo Federica and Tricot Guido, Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116838
DOI https://dx.doi.org/10.2174/138920106779116838 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Current Topics in Medicinal Chemistry NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Editorial (Thematic Issue: New Therapeutic Bearings for Repositioned Drugs)
Current Topics in Medicinal Chemistry Bronchiolitis Obliterans Following Lung Transplantation and Stem Cell Transplantation in Pediatric Patients
Current Pediatric Reviews An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry